医药生物行业：ADHD治疗需求释放，缓释技术构筑核心壁垒

Investment Rating - The report maintains an "Outperform" rating for the pharmaceutical and biotechnology industry [4] Core Insights - Attention Deficit Hyperactivity Disorder (ADHD) is a prevalent mental health issue among children and adolescents in China, with a prevalence rate of 6.26% (approximately 23 million people), and a low actual treatment rate of only 10% [1][11] - Methylphenidate (盐酸哌甲酯) is the first-line medication for ADHD treatment, with a significant market potential as the demand for ADHD treatment continues to grow [1][2] - The market for methylphenidate extended-release tablets is projected to reach approximately 7.333 billion yuan by 2035, driven by increasing diagnosis rates and treatment demand [2][35] Summary by Sections ADHD Overview - ADHD is characterized by persistent attention deficits and/or hyperactivity-impulsivity symptoms that can negatively impact various life domains [11] - The global prevalence of ADHD among children and adolescents is about 7.2%, with significant economic burdens associated with untreated cases [11][12] Methylphenidate Market Dynamics - Methylphenidate's market share is expected to grow from 56.13% in 2021 to 74.64% by mid-2025, indicating a strengthening market position [2][42] - The potential market size for methylphenidate in children and adolescents is estimated at 2.875 billion yuan by 2035, while in adults, it is projected to reach 4.458 billion yuan [2][35] Industry Chain Analysis - The methylphenidate industry chain is characterized by concentrated competition among a few key players in the raw material and drug manufacturing sectors [3][51] - The report highlights the competitive advantages of companies like Johnson & Johnson and Liyuan Pharmaceutical, which utilize advanced controlled-release technologies [28][32] Key Companies and Financial Projections - The report identifies key companies involved in the production of methylphenidate, including Johnson & Johnson and Liyuan Pharmaceutical, with financial forecasts indicating significant growth potential [46][47] - The introduction of generic versions of methylphenidate is expected to create competitive pressure on existing products, potentially leading to price reductions and increased market accessibility [47]